Arctic Bioscience are pleased to announce that we have been invited to present at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in the session ‘The Perfect Dose: Innovating Drugs and Drug Delivery’.
Our Medical Director, Runhild Gammelsæter, will be presenting our latest pipeline project, ABS403, with the aim to promote resolution of inflammation and support neuroprotection in glaucoma. This eye disease does not currently have a cure and leads to blindness.
The project was initiated based on encouraging clinical signals from a pilot study in glaucoma (POAG).
As we prepare for the next stages, we are actively seeking partners and investors to join us in advancing ABS403 into further clinical development.
Read more about the event: https://glaucoma360.org/
Read more about the promising pilot trial by Luo et al: https://doi.org/10.1007/s10792-025-03693-1
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.